On June 29, 2026, the U.S. Food and Drug Administration (FDA) published a significant proposed rule in the Federal Register titled “Establishment Registration and Product Listing for Tobacco Products.” The proposal would create a new regulatory framework under 21 CFR Part 1108 and substantially expand FDA oversight of both domestic and foreign tobacco product manufacturers supplying products to the U.S. market. 

For businesses involved in vapor products, nicotine products, ENDS manufacturing, importing, or distribution, this proposal represents another major step toward increased supply-chain transparency and enhanced enforcement capabilities targeting unauthorized products. 

 

What Is the FDA Proposing? 

 

The proposed rule would formalize registration and product listing requirements for tobacco product manufacturers by establishing standardized procedures, formats, and reporting obligations. 

While domestic manufacturers have operated under registration and listing expectations for years, the biggest shift in this proposal is the expansion of those obligations to foreign manufacturers whose products enter the U.S. market. 

According to FDA, the goal is to improve oversight of tobacco products sold or imported into the United States and strengthen the agency’s ability to identify unauthorized or non-compliant products. 

The proposal builds heavily on FDA’s longstanding 2009 guidance regarding establishment registration and product listing but would now codify many of those expectations into binding regulations. 

 

Why This Matters to the Industry 

 

The proposed rule directly addresses what FDA describes as a major regulatory gap: foreign tobacco manufacturers currently are not subject to the same registration and product listing requirements as domestic facilities unless FDA specifically issues regulations requiring it. 

As a result, FDA argues it has lacked visibility into many overseas manufacturers producing products for the U.S. market — particularly within the rapidly evolving ENDS category. 

If finalized, the rule would significantly expand FDA’s insight into the global tobacco supply chain while giving the agency additional tools to pursue enforcement actions against products it considers unauthorized or non-compliant. 

For importers and distributors, this could also mean increased scrutiny at ports of entry and additional documentation requirements tied to product identification and manufacturer compliance. 

 

Key Changes Proposed by FDA 

 

One of the most significant elements of the proposal is the expanded definition of “manufacturer.” 

Under the proposed framework, FDA would not only regulate companies physically producing products, but also entities involved in: 

• Product specification development  
• Contract manufacturing  
• Repackaging and relabeling  
• Bulk tobacco product manufacturing  

 

This means companies that outsource production but maintain control over product design or specifications may still fall under FDA’s definition of a manufacturer and inherit corresponding compliance obligations. 

The proposal would also require: 

• Electronic submission of registration and product listing information through FDA systems  
• Annual establishment re-registration by December 31  
• Product listing updates twice per year  
• Registration within five business days for domestic manufacturers beginning operations  
• Registration by foreign manufacturers before products are imported into the United States  

 

Product Information Requirements Could Expand Significantly 

 

The proposed rule would require manufacturers to provide extensive identifying information for every listed tobacco product. 

For ENDS and nicotine products, this could include: 

• Brand and subbrand names  
• Product categories and subcategories  
• Package type and quantity  
• Characterizing flavors  
• Nicotine source  
• Nicotine concentration  
• E-liquid volume  
• Battery capacity  
• Wattage  

 

Additionally, manufacturers would be required to maintain records related to labeling, advertising, and consumer information for at least four years after use. 

FDA states these records would assist the agency in evaluating compliance with marketing restrictions, labeling requirements, and unauthorized health claims. 

 

Foreign Manufacturers Face New Compliance Pressure 

 

The proposal places particular emphasis on foreign facilities manufacturing products intended for the U.S. market. 

If finalized, overseas manufacturers would become subject to FDA inspection authority and would need to ensure they can provide detailed product and operational information upon request. 

This creates several immediate considerations for foreign manufacturers and their U.S. partners: 

• Which facilities and products would fall under the rule  
• Whether facilities are prepared for potential FDA inspections  
• How registration obligations could impact import timelines  
• Whether required product-specific information is already organized and accessible 
• Whether historical labeling and advertising records are being retained appropriately  

For importers and distributors relying heavily on overseas manufacturing partners, the rule could introduce additional operational and supply-chain challenges if facilities are unprepared for the new requirements. 

 

Part of a Larger Enforcement Strategy 

 

The proposed rule also reflects the administration’s broader focus on illegal and unauthorized tobacco products entering the U.S. market. 

FDA specifically references Executive Order 14212 and the Make America Healthy Again Commission’s 2025 strategy report, signaling that this proposal aligns with larger federal efforts targeting unauthorized ENDS products and increasing oversight of imported nicotine products. 

For many in the industry, this proposal reinforces the reality that FDA continues moving toward tighter supply-chain monitoring, enhanced import enforcement, and broader data collection across the tobacco and nicotine marketplace. 

 

Public Comments Open Through September 14 

 

FDA is currently accepting public comments on the proposed rule before determining whether to issue a final version. 

Manufacturers, importers, distributors, and industry stakeholders may want to carefully review the proposal and evaluate how the requirements could affect their operations, compliance systems, and supply chains. 

The public comment period closes on September 14, 2026. 

Companies can review the proposal and submit comments through the Federal Register and Regulations.gov. 

 

What Comes Next? 

 

While the rule is still in the proposal stage, it represents another clear signal that FDA intends to expand oversight beyond traditional domestic manufacturing and gain greater visibility into the global tobacco and nicotine supply chain. 

For businesses operating in the vapor and alternative nicotine industries, now is the time to evaluate registration processes, supplier relationships, recordkeeping systems, and product data management before these requirements potentially become mandatory.